H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)

November 5, 2024 8:06 AM EST Send to a Friend
H.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $30.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login